Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results(1)

Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Lipid Res
Prif Awduron: Yang, Xiaohong, Lee, Sang-Rok, Choi, Yun-Seok, Alexander, Veronica J., Digenio, Andres, Yang, Qingqing, Miller, Yury I., Witztum, Joseph L., Tsimikas, Sotirios
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: The American Society for Biochemistry and Molecular Biology 2016
Pynciau:
Patient-Oriented and Epidemiological Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4808774/
https://ncbi.nlm.nih.gov/pubmed/26848137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M066399
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg